Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 7 (2-3) , 163-172
- https://doi.org/10.1007/bf00170853
Abstract
Summary The effect of leucovorin (LV) given in various doses and schedules on the in vivo antitumor activity and toxicity of 5-fluorouracil (5FU) was studied in two murine colon cancer lines, i.e., Colon 26 (relatively resistant to 5FU) and Colon 38 (5FU sensitive), maintained in Balb-c and C57B1/6 mice, respectively. Mice were treated weekly with 5FU at the maximum tolerated dose, alone and in combination with LV. In Colon 26, neither simultaneous administration of 5FU and LV nor 5FU combined with delayed administration of LV potentiated the antitumor activity of 5FU. LV given twice — 1 hr before (50 mg/kg) and then together (50 mg/kg) with 5FU (100 mg/kg) — gave significantly better delay of tumor growth of both tumor lines than 5FU did alone (100 mg/kg). No differences were found after a total LV dose of 100 or 200 mg/kg. Delayed administration of uridine (3500 mg/kg) allowed the use of higher 5FU doses, which improved the antitumor effect on Colon 26. Systemic toxicity led to moderate weight loss in treated mice, but was comparable for mice treated with 5FU alone or combined with LV. Hematological toxicity consisted of moderate leukopenia (nadir 40%), which was observed with the most active schedule and was less severe than with 5FU alone. This schedule did not cause thrombocytopenia, but after discontinuation the thrombocyte count showed an overshoot. Addition of uridine to this schedule reduced hematological toxicity only slightly. It is concluded that LV potentiated the antitumor activity of 5FU against two solid tumor lines, i.e., a relatively resistant and a sensitive murine colon carcinoma, and that toxicity was moderate.Keywords
This publication has 38 references indexed in Scilit:
- Reversal of 5-Fluorouracil-Induced Myelosuppression by Prolonged Administration of High-Dose UridineJNCI Journal of the National Cancer Institute, 1989
- Failure of High-Dose Leucovorin To Improve Therapy With the Maximally Tolerated Dose of 5-Fluorouracil: A Murine Study With Clinical Relevance?JNCI Journal of the National Cancer Institute, 1988
- Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenograftsEuropean Journal of Cancer and Clinical Oncology, 1986
- Phase II study with high-dose N5–10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancerEuropean Journal of Cancer and Clinical Oncology, 1985
- Decreased host toxicity in vivo during chronic treatment with 5-flourouracilCancer Chemotherapy and Pharmacology, 1985
- The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenograftsEuropean Journal of Cancer and Clinical Oncology, 1982
- The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cellsBiochemical and Biophysical Research Communications, 1981
- Chemotherapy of Gastrointestinal CancerNew England Journal of Medicine, 1978
- Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanismBiochemistry, 1978
- Thymidylate synthetase - a target enzyme in cancer chemotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1977